Related Experiment Video
Updated: Feb 10, 2026

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
Published on: January 10, 2013
Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice
Antoni Sicras-Mainar1, Javier Rejas-Gutiérrez2, Maria Perez-Paramo3
1ClinicResearch, Tiana, Barcelona, Spain.
Aim:
To analyze the cost of peripheral neuropathic pain (PNP) treatment with pregabalin or gabapentin at therapeutic doses in routine clinical practice.
Methods:
Analysis of a retrospective, observational study of electronic medical records of patients treated for PNP with therapeutic doses of pregabalin or gabapentin, with 2 years' follow-up, considering PNP type, comorbidities, concomitant analgesia and resource use.
Results:
The weighted total average cost/patient was lower for pregabalin than gabapentin (€2464 [2197-2730] vs €3142 [2670-3614]; p = 0.014) due to significantly lower both healthcare and non-healthcare costs. This is explained by a significantly lower use of concomitant analgesia, fewer primary care visits and fewer days of sick leave.
Conclusion:
At therapeutic doses, pregabalin was found to have lower healthcare and non-healthcare costs than gabapentin in routine practice.
Related Concept Videos
Pain
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Therapeutic Index
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...

